KR102472483B1 - Cosmetic composition having exfoliating effect and moisturizing effect - Google Patents
Cosmetic composition having exfoliating effect and moisturizing effect Download PDFInfo
- Publication number
- KR102472483B1 KR102472483B1 KR1020220006017A KR20220006017A KR102472483B1 KR 102472483 B1 KR102472483 B1 KR 102472483B1 KR 1020220006017 A KR1020220006017 A KR 1020220006017A KR 20220006017 A KR20220006017 A KR 20220006017A KR 102472483 B1 KR102472483 B1 KR 102472483B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- comparative example
- skin
- salicylic acid
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000002537 cosmetic Substances 0.000 title claims abstract description 40
- 230000000694 effects Effects 0.000 title claims abstract description 31
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 25
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 39
- 229920006037 cross link polymer Polymers 0.000 claims abstract description 39
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 39
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 39
- IXIGWKNBFPKCCD-UHFFFAOYSA-N 2-hydroxy-5-octanoylbenzoic acid Chemical compound CCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 IXIGWKNBFPKCCD-UHFFFAOYSA-N 0.000 claims abstract description 23
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims abstract description 20
- 235000012209 glucono delta-lactone Nutrition 0.000 claims abstract description 20
- 229960003681 gluconolactone Drugs 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000008213 purified water Substances 0.000 claims abstract description 14
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 claims abstract description 10
- -1 pH adjusters Substances 0.000 claims description 16
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000006096 absorbing agent Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000001166 anti-perspirative effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000003213 antiperspirant Substances 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 239000002826 coolant Substances 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 150000004679 hydroxides Chemical class 0.000 claims description 3
- 239000001023 inorganic pigment Substances 0.000 claims description 3
- 239000012860 organic pigment Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 239000002516 radical scavenger Substances 0.000 claims description 3
- 239000003352 sequestering agent Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 229940123457 Free radical scavenger Drugs 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 230000021148 sequestering of metal ion Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 74
- 229920001273 Polyhydroxy acid Polymers 0.000 description 64
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 64
- 210000003491 skin Anatomy 0.000 description 37
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 31
- 229960004889 salicylic acid Drugs 0.000 description 31
- 125000001931 aliphatic group Chemical group 0.000 description 29
- 108010076876 Keratins Proteins 0.000 description 26
- 102000011782 Keratins Human genes 0.000 description 26
- 206010040844 Skin exfoliation Diseases 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 14
- 229940061720 alpha hydroxy acid Drugs 0.000 description 11
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 11
- 210000000434 stratum corneum Anatomy 0.000 description 11
- 238000004299 exfoliation Methods 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 210000004927 skin cell Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 240000007817 Olea europaea Species 0.000 description 4
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 238000012017 passive hemagglutination assay Methods 0.000 description 4
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 4
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000001047 desmosome Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 229940099563 lactobionic acid Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- JEZPYWJABYHHDF-UHFFFAOYSA-N 14-methylpentadecyl 2-hydroxybenzoate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)C1=CC=CC=C1O JEZPYWJABYHHDF-UHFFFAOYSA-N 0.000 description 2
- CZVOIAOPRGNENY-UHFFFAOYSA-N 2-butyloctyl 2-hydroxybenzoate Chemical compound CCCCCCC(CCCC)COC(=O)C1=CC=CC=C1O CZVOIAOPRGNENY-UHFFFAOYSA-N 0.000 description 2
- WGPVWXXJNUNBNB-UHFFFAOYSA-N 2-carboxyphenolate;2-hydroxyethylazanium Chemical compound NCCO.OC(=O)C1=CC=CC=C1O WGPVWXXJNUNBNB-UHFFFAOYSA-N 0.000 description 2
- PJTNSWOJMXNNFG-UHFFFAOYSA-N 8-methylnonyl 2-hydroxybenzoate Chemical compound CC(C)CCCCCCCOC(=O)C1=CC=CC=C1O PJTNSWOJMXNNFG-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 2
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 2
- JYTUSYBCFIZPBE-UHFFFAOYSA-N Maltobionic acid Natural products OC(=O)C(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O JYTUSYBCFIZPBE-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 150000001491 aromatic compounds Chemical group 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- AVVIDTZRJBSXML-UHFFFAOYSA-L calcium;2-carboxyphenolate;dihydrate Chemical compound O.O.[Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O AVVIDTZRJBSXML-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- NDYACOBUVVOTSV-UHFFFAOYSA-N hexadecan-7-yl 2-hydroxybenzoate Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)C1=CC=CC=C1O NDYACOBUVVOTSV-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 2
- 229940072082 magnesium salicylate Drugs 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- FRMWBRPWYBNAFB-UHFFFAOYSA-M potassium salicylate Chemical compound [K+].OC1=CC=CC=C1C([O-])=O FRMWBRPWYBNAFB-UHFFFAOYSA-M 0.000 description 2
- 229960003629 potassium salicylate Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IFYFNVDTVZKNBZ-UHFFFAOYSA-N tetradecyl 2-hydroxybenzoate Chemical compound CCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1O IFYFNVDTVZKNBZ-UHFFFAOYSA-N 0.000 description 2
- VLMWBWYAHNRUGC-UHFFFAOYSA-N tridecyl 2-hydroxybenzoate Chemical compound CCCCCCCCCCCCCOC(=O)C1=CC=CC=C1O VLMWBWYAHNRUGC-UHFFFAOYSA-N 0.000 description 2
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- PDHFSBXFZGYBIP-UHFFFAOYSA-N 2-[2-(2-hydroxyethylsulfanyl)ethylsulfanyl]ethanol Chemical compound OCCSCCSCCO PDHFSBXFZGYBIP-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- ZWXYEWJNBYQXLK-UHFFFAOYSA-N azanium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [NH4+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O ZWXYEWJNBYQXLK-UHFFFAOYSA-N 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000037310 combination skin Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108010075526 keratohyalin Proteins 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 1
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229940094541 polyglycerin-10 Drugs 0.000 description 1
- 229940099549 polyglycerin-3 Drugs 0.000 description 1
- 229940110977 polyglycerin-4 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 229940079776 sodium cocoyl isethionate Drugs 0.000 description 1
- 229940007636 sodium lauroyl methyl isethionate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- NVIZQHFCDBQNPH-UHFFFAOYSA-M sodium;2-dodecanoyloxypropane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(C)CS([O-])(=O)=O NVIZQHFCDBQNPH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 화장료 조성물에 관한 것으로 더 자세하게는 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 동시에 포함하여, 각질제거효과와 보습효과를 동시에 갖는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition, and more particularly, to a cosmetic composition containing polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer at the same time, having both an exfoliating effect and a moisturizing effect. It is about.
피부의 가장 중요한 역할은 외부의 세균 침입과 손상으로부터 피부를 보호하는 방어 장벽(defense barrier)의 역할을 함과 동시에 내부로부터의 열과 수분 손실을 방지하는 것이다. 피부는 여러 개의 층으로 구성되어 있는데, 이 가운데 가장 바깥에 위치하는 것을 표피(epidermis)라 하고, 그 아래로 진피, 피하 지방층의 세 부분으로 분류된다.The most important role of the skin is to act as a defense barrier to protect the skin from bacterial invasion and damage from the outside, and to prevent heat and moisture loss from the inside. The skin is composed of several layers, the outermost of which is called the epidermis, and it is classified into three parts: the dermis and the subcutaneous fat layer.
표피는 다시 각질층, 과립층, 유극층, 기저층으로 세분되는데, 기저층에서 생성된 표피 세포는 14일 걸려 과립층까지 올라오고 과립층에서 케라토히알린(Keratohyalin)의 작용으로 각질화가 시작된다. 이미 세포 속의 체액은 빠져나가 세포는 납작해진 상태로 각질화가 진행되며, 세포의 핵, 세포질과 세포소기관은 퇴화되고, 케라토히알린으로 교체되어 엘레이딘(Eleidin)으로 다시 변화되었다가 마지막 단계인 각질로 바뀌면서 세포의 일생은 끝나며 각질층으로 밀려 올라간다. 각질층은 분화된 표피 세포(각질세포)와 그 사이를 채우고 있는 세포간지질(Skin Lipid)로 구성되며 체내 물질이 외부로 나가는 것을 막아주고 외부의 물리적, 화학적, 생물학적 자극으로부터 인체를 보호하는 방어 기능을 한다.The epidermis is again subdivided into the stratum corneum, the granular layer, the spinous layer, and the basal layer. Epidermal cells generated in the basal layer rise to the granular layer over 14 days, and keratinization begins in the granular layer by the action of keratohyalin. The fluid inside the cell is already drained, and the cell flattens and undergoes keratinization. As the cell's life ends, it is pushed up to the stratum corneum. The stratum corneum is composed of differentiated epidermal cells (keratinocytes) and intercellular lipids filling the space between them. It has a defense function that prevents internal substances from escaping to the outside and protects the human body from external physical, chemical, and biological stimuli. do
각질 세포는 데스모좀이라 불리우는 단백질에 의하여 연결되어 있으며, 각질층 상부로 올라갈수록 데스모좀은 분해되어 각질 세포 간 응집력이 약화되고 최종적으로 각질 세포는 피부로부터 분리되어 떨어져 나간다. 정상 피부의 경우 각질층은 15~20층으로 구성되고 이들이 완전히 분리되는 데는 15~20일이 소요된다. 그러나 나이가 들어감에 따라 피부 구성 성분인 표피, 진피 및 피하 조직의 두께가 얇아지고 피부의 수분 함량이 급격히 감소하며, 피부에 탄력을 주는 ECM(Extracellular Matrix) 성분의 변화로 인해 피부가 탄력을 잃고 주름이 지게 되며 각질층의 분리가 정상보다 늦어져 각질층이 두꺼워지고(각질중층화) 피부가 활력을 잃게 된다.Keratinocytes are connected by proteins called desmosomes, and as they go up the stratum corneum, desmosomes are decomposed and cohesion between keratinocytes is weakened, and finally keratinocytes are separated from the skin and fall off. In the case of normal skin, the stratum corneum is composed of 15 to 20 layers, and it takes 15 to 20 days for them to completely separate. However, with age, the thickness of the epidermis, dermis, and subcutaneous tissue, which are components of the skin, thins, the moisture content of the skin decreases rapidly, and the skin loses elasticity due to changes in the ECM (Extracellular Matrix) component that gives skin elasticity. Wrinkles occur, and the separation of the stratum corneum is delayed than normal, resulting in thickening of the stratum corneum (stratification of stratum corneum) and loss of vitality of the skin.
각질중층화는 주로 피부의 보습력 감소, 데스모좀 분해 효소의 생성 및 활성감소, 세포 활성 저하 등에 기인하며 피부노화, 자외선노출, 공해 등이 유발 요인이 된다. 이러한 내, 외적인 요인에 의해 두꺼워진 각질층을 외부에서 인위적으로 얇게 해주면 각질층 밑에 있는 살아있는 세포의 활성 혹은 재생이 증가되어 피부가 부드러워지며, 주름제거, 여드름 발생 억제 및 치료 등의 효과가 있어 자극이 유발되지 않는 범위 내에서 각질중층화를 해소하려는 연구가 많이 진행되고 있다.The stratum corneum is mainly caused by a decrease in the moisturizing ability of the skin, a decrease in the production and activity of desmosome degrading enzymes, and a decrease in cell activity, and is caused by skin aging, exposure to ultraviolet rays, and pollution. If the stratum corneum thickened by these internal and external factors is artificially thinned from the outside, the activity or regeneration of living cells under the stratum corneum increases, making the skin softer, removing wrinkles, suppressing and treating acne, and causing irritation. A lot of research is being conducted to solve keratin stratification within a range that is not possible.
각질중충화를 해소하기 위해서는 피부를 물리적으로 문지르거나 화학적 박피술을 이용한다. 특히 화학적 박피는 잔주름 개선, 거친 피부 완화, 잡티제거 등의 부가적인 효과가 있다. 화학적 박피에 사용되는 물질은 기본적으로 AHA(Alpha-Hydroxy Acid)와 BHA(Beta-Hydroxy Acid)가 주로 사용되어 왔다.In order to relieve keratin neutralization, the skin is physically rubbed or chemical peeling is used. In particular, chemical peeling has additional effects such as improvement of fine wrinkles, relief of rough skin, and removal of blemishes. As materials used for chemical peeling, AHA (Alpha-Hydroxy Acid) and BHA (Beta-Hydroxy Acid) have been mainly used.
그 중에서도 알파하이드록시애씨드(AHA: α-Hydroxy Acid)은 카르복시산(Carboxylic Acid)의 α 위치에 있는 탄소에 알코올기(Alcohol Group) 또는 하이드록시기(Hydroxy Group)를 첨가한 화합물로 각질 세포의 이온결합 에너지를 낮추어 각질을 제거하거나 새로운 세포의 형성을 촉진하여 피부가 노화되면서 길어지는 각질화과정의 주기를 짧게 하여 피부 세포의 활성을 촉진시켜 피부를 개선하는 작용을 한다. 또한, 섬유아세포(Fibroblast)에 의한 콜라겐(Collagen)과 엘라스틴(Elastin)의 생성을 촉진하여 피부를 탄력있고, 부드럽게 하고 진피의 중요한 세포외 기질 성분인 뮤코폴리사카라이드(Mucopolysaccharide)의 생성을 촉진하여 피부보습을 증진시킬 수 있다. 현재 알파 히드록시산을 유효 성분으로 하여 피부 각질을 제거하는 화장료 조성물에 대한 개발이 활발히 진행 중이다. 그러나, 알파 히드록시산은 피부에 대한 자극이 너무 커서 각질 제거 용도로 사용하기에는 문제점이 있었다.Among them, alpha hydroxy acid (AHA: α-Hydroxy Acid) is a compound in which an alcohol group or a hydroxy group is added to the carbon at the α position of carboxylic acid. It works to improve the skin by promoting the activation of skin cells by lowering the binding energy to remove dead skin cells or by promoting the formation of new cells to shorten the cycle of the keratinization process that gets longer as the skin ages. In addition, it promotes the production of collagen and elastin by fibroblasts to make the skin elastic and soft, and promotes the production of mucopolysaccharide, an important extracellular matrix component of the dermis. It can improve skin hydration. Currently, development of a cosmetic composition that uses alpha hydroxy acid as an active ingredient to remove dead skin cells is in progress. However, alpha hydroxy acid has a problem in that it is too irritating to the skin to be used for exfoliation.
한편, 폴리하이드록시애씨드(PHA)는 지방족 화합물(aliphatic) 또는 방향족 화합물의 사슬에 두 개 또는 그 이상의 하이드록시기(hydroxy group)가 결합되어 있는 유기 카르복실산이다. 상기 알파하이드록시산(AHA)은 알파 위치에 하이드록시기를 포함하는데 비해, 상기 PHA는 알파 위치를 포함한 여러 위치에 하이드록시기를 포함하고 있다. PHA에서 하이드록시기는 중성을 띄며, 카르복시기는 산도를 나타낸다.On the other hand, polyhydroxy acid (PHA) is an organic carboxylic acid in which two or more hydroxy groups are bonded to an aliphatic or aromatic compound chain. While the alpha hydroxy acid (AHA) contains a hydroxyl group at an alpha position, the PHA contains a hydroxyl group at various positions including the alpha position. In PHA, the hydroxy group is neutral, and the carboxy group represents acidity.
화장료 조성물로서의 PHA는 피부의 각질 세포의 이온결합 에너지를 낮추어 과각질을 제거하거나 새로운 세포의 형성을 촉진하여 피부가 노화되면서 길어지는 각질화과정의 주기를 짧게 하여 피부 세포의 활성을 촉진시켜 피부를 개선하는 효과를 지니고 있다.PHA as a cosmetic composition lowers the ion binding energy of keratinocytes in the skin to remove excess keratin or promotes the formation of new cells, thereby shortening the cycle of keratinization process that gets longer as the skin ages, promoting the activity of skin cells to improve skin has the effect of
다만, 종래의 각질제거 성분은 단독으로 사용 시 그 효과가 미약하다는 문제를 갖고 있었으며, 또한 각질제거와 함께 나타나는 수분의 증발에 대한 대처도 미흡하다는 평가를 받고 있었다. 이에 따라, 각질제거 기능이 개선되고, 피부 보습 효과 역시 종래에 비해 개선될 수 있도록 그 조합과 수치를 적절히 고려해야 할 필요성이 있다.However, the conventional exfoliating component has a problem that its effect is weak when used alone, and it has also been evaluated that it is insufficient to cope with the evaporation of moisture that occurs along with the exfoliation. Accordingly, there is a need to properly consider the combination and value so that the exfoliation function can be improved and the skin moisturizing effect can also be improved compared to the prior art.
상기와 같은 문제점을 해결하기 위하여 본 발명은 화장료 조성물에 관한 것으로 더 자세하게는 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 동시에 포함하여, 각질제거효과와 보습효과를 동시에 갖는 화장료 조성물을 제공하는데 목적이 있다.In order to solve the above problems, the present invention relates to a cosmetic composition, and more specifically, to a cosmetic composition comprising polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer at the same time, exfoliating effect. And it is an object to provide a cosmetic composition having a moisturizing effect at the same time.
상기와 같은 문제점을 해결하기 위하여 본 발명은 글루코노락톤, 락토바이오닉애씨드, 말토바이오닉애씨드로 이루어진 군에서 선택된 어느 하나 이상의 폴리하이드록시애씨드(PHA))와; 카프릴로일살리실릭애씨드, 칼슘살리실레이트, 마그네슘살리실레이트, 엠이에이-살리실레이트, 포타슘살리실레이트, 소듐살리실릭애씨드, 티이에이-살리실레이트)과 살리실릭애씨드의 에스터(부틸옥틸살리실레이트, C12-15 알킬살리실레이트, 헥실데실살리실레이트, 아이소 세틸살리실레이트, 아이소데실살리실레이트, 에틸헥실살리실레이트, 메틸살리실레이트, 미리스틸살리실레이트, 트리데실살리실레이트로 이루어진 군에서 선택된 어느 하나 이상의 지방족 살리실릭애씨드(LHA); 및, 소듐하이알루로네이트크로스폴리머;를 포함하여, 각질제거효과 및 보습효과를 갖는 것을 특징으로 하는 화장료 조성물을 제공한다.In order to solve the above problems, the present invention is any one or more polyhydroxy acid (PHA) selected from the group consisting of gluconolactone, lactobionic acid, and maltobionic acid); Capryloyl Salicylic Acid, Calcium Salicylate, Magnesium Salicylate, MEA-Salicylate, Potassium Salicylate, Sodium Salicylic Acid, TEA-Salicylate) and Esters of Salicylic Acid (Butyloctyl Salicylate, C12-15 Alkyl Salicylate, Hexyldecyl Salicylate, Iso Cetyl Salicylate, Isodecyl Salicylate, Ethylhexyl Salicylate, Methyl Salicylate, Myristyl Salicylate, Tridecyl Salicylate It provides a cosmetic composition characterized by having an exfoliation effect and a moisturizing effect, including any one or more aliphatic salicylic acid (LHA) selected from the group consisting of lysylates; and sodium hyaluronate crosspolymer.
또한, 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머는 각각 0.001 ~ 10.0중량%로 포함하는 것을 특징으로 한다.In addition, the polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer are characterized in that each comprises 0.001 to 10.0% by weight.
또한, 상기 폴리하이드록시애씨드(PHA) 중 글루코노락톤(Gluconolactone)을 택하여 사용하며, 지방족 살리실릭애씨드(LHA) 중 카프릴로일살리실릭애씨드(Capryloyl Salicylic Acid)를 택하여 사용하는 것을 특징으로 한다.In addition, gluconolactone is selected and used among the polyhydroxy acid (PHA), and capryloyl salicylic acid is selected and used among aliphatic salicylic acid (LHA). do.
또한, 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머 외에, 계면활성제, 폴리올, 점증제, 용해제, 착색제, 색소, 보존제, 안정화제, 에몰리언트제, 자외선 흡수제, 방부제, 살균제, 유화제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 정제수, 분산제, 충전제, 감미료, 비타민, 자유-라디칼 스케빈저, 금속이온 봉쇄제, 냉감제, 제한제, 수산화염 중 어느 하나 이상의 첨가제를 더 포함하는 것을 특징으로 한다.In addition, in addition to the polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer, surfactants, polyols, thickeners, solubilizers, colorants, pigments, preservatives, stabilizers, emollients, UV absorbers, preservatives, bactericides, emulsifiers, antioxidants, pH adjusters, organic and inorganic pigments, fragrances, purified water, dispersants, fillers, sweeteners, vitamins, free-radical scavengers, sequestrants, cooling agents, antiperspirants, It is characterized in that it further comprises any one or more additives of the hydroxide salt.
또한, 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머의 혼합물을 포함하여, 로션, 크림, 젤, 수용성 리퀴드, 수중유(O/W)형 화장품, 유중수(W/O)형 화장품 및 실리콘중수(W/Si)형 화장품, 용액, 현탁액, 유탁액, 페이스트, 파우더, 비누, 계면활성제-함유 클린징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 또는 스프레이 중 어느 하나의 제형으로 제형화 되는 것을 특징으로 한다.In addition, lotions, creams, gels, water-soluble liquids, oil-in-water (O/W) cosmetics, including mixtures of polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer , water-in-oil (W/O) cosmetic and water-in-silicon (W/Si) cosmetic, solution, suspension, emulsion, paste, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax It is characterized in that it is formulated in any one formulation of foundation or spray.
본 발명에 따른 각질제거효과와 보습효과를 동시에 갖는 화장료 조성물은 화장료 조성물에 관한 것으로 더 자세하게는 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 동시에 포함하여, 각질제거효과와 보습효과를 동시에 가지며 그 효과가 우수하다.The cosmetic composition having both exfoliation and moisturizing effects according to the present invention relates to a cosmetic composition, and more specifically, includes polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer at the same time. Thus, it has an exfoliating effect and a moisturizing effect at the same time, and the effect is excellent.
도 1은 실시예 1 내지 7 및 비교예 1 내지 12에 대한 각질 감소 효과를 나타낸 그래프.
도 2는 비교예 3, 실시예 4, 비교예 6, 비교예 7, 비교예 8, 비교예 9, 비교예 10, 비교예 11 및 비교예 12를 사용한 피부의 각질에 대한 현미경 촬영 사진.
도 3은 실시예 1 내지 7 및 비교예 1 내지 12에 대한 보습효과를 나타낸 그래프.1 is a graph showing the keratin reduction effect for Examples 1 to 7 and Comparative Examples 1 to 12.
Figure 2 is a micrograph of the keratin of the skin using Comparative Example 3, Example 4, Comparative Example 6, Comparative Example 7, Comparative Example 8, Comparative Example 9, Comparative Example 10, Comparative Example 11 and Comparative Example 12.
Figure 3 is a graph showing the moisturizing effect for Examples 1 to 7 and Comparative Examples 1 to 12.
이하의 본 발명에 관한 상세한 설명들은 본 발명이 실시될 수 있는 실시 예이고 해당 실시 예의 예시로써 도시된 첨부 도면을 참조한다. 이들 실시 예는 당 업자가 본 발명의 실시에 충분하도록 상세히 설명된다. The detailed description of the present invention below refers to the accompanying drawings shown as examples of embodiments in which the present invention can be practiced. These embodiments are described in detail so that those skilled in the art will be able to practice the present invention.
본 발명의 다양한 실시 예는 서로 다르지만 상호 배타적일 필요는 없음이 이해되어야 한다. It should be understood that the various embodiments of the present invention are different, but need not be mutually exclusive.
예를 들어, 여기에 기재되어 있는 특정 형상, 구조 및 특성은 일 실시 예에 관련하여 본 발명의 사상 및 범위를 벗어나지 않으면서 다른 실시 예로 구현될 수 있다. 예를 들어, 각질량을 측정하는데 사용되는 기구는 will cam사의 피부진단기 제품을 이용한 것일 수 있다. 각질세포의 현미경사진 촬영에 이용할 수 있는 염료는 댄실 클로라이드, 다이히드록시아세톤, DAPI 중 어느 하나일 수 있다. For example, specific shapes, structures, and characteristics described herein may be implemented in one embodiment in another embodiment without departing from the spirit and scope of the invention. For example, an instrument used to measure the amount of keratin may be a skin diagnostic device from will cam. A dye usable for taking micrographs of keratinocytes may be any one of dansyl chloride, dihydroxyacetone, and DAPI.
또한, 각각의 기재된 실시 예 내의 개별 구성요소의 위치 또는 배치는 본 발명의 사상 및 범위를 벗어나지 않으면서 변경될 수 있음이 이해되어야 한다.Additionally, it should be understood that the location or arrangement of individual components within each described embodiment may be changed without departing from the spirit and scope of the invention.
따라서 후술되는 상세한 설명은 한정적인 의미로서 취하려는 것이 아니며, 본 발명의 범위는 적절하게 설명된다면 그 청구항들이 주장하는 것과 균등한 모든 범위와 더불어 첨부된 청구항에 의해서만 한정된다. 도면에서 유사한 참조부호는 여러 측면에 걸쳐서 동일하거나 유사한 기능을 지칭한다. Accordingly, the detailed description set forth below is not to be taken in a limiting sense, and the scope of the present invention, if properly described, is limited only by the appended claims, along with all equivalents as claimed by those claims. Like reference numbers in the drawings indicate the same or similar function throughout the various aspects.
본 발명에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. The terms used in the present invention have been selected from general terms that are currently widely used as much as possible while considering the functions in the present invention, but these may vary depending on the intention of a person skilled in the art or precedent, the emergence of new technologies, and the like.
또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.In addition, in a specific case, there is also a term arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the invention. Therefore, the term used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, not simply the name of the term.
본 발명에서 어떤 부분이 어떤 구성요소를 “포함”한다고 할 때, 이는 특별히 반대되는 기재가 없는 한, 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함할 수 있음을 의미한다.In the present invention, when a part "includes" a certain component, it means that it may further include other components, not excluding other components, unless otherwise stated.
이하, 본 발명에 따른 각질제거효과와 보습효과를 동시에 갖는 화장료 조성물에 대하여 자세히 설명한다.Hereinafter, the cosmetic composition having both an exfoliating effect and a moisturizing effect according to the present invention will be described in detail.
본 발명에 따른 각질제거효과와 보습효과를 동시에 갖는 화장료 조성물은 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 포함하여, 각질제거효과와 보습효과를 동시에 갖는다.The cosmetic composition having both an exfoliating effect and a moisturizing effect according to the present invention includes polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer, and has an exfoliating effect and a moisturizing effect. have at the same time
상기 폴리하이드록시애씨드(PHA, Polyhydroxy Acids)는 지방족 화합물(aliphatic) 또는 방향족 화합물의 사슬에 두 개 또는 그 이상의 하이드록시기(hydroxy group)가 결합되어 있는 유기 카르복실산이다. 알파하이드록시산(AHA)은 알파 위치에 하이드록시기를 포함하는데 비해, 상기 폴리하이드록시애씨드(PHA)는 알파 위치를 포함한 여러 위치에 하이드록시기를 포함하고 있다. PHA에서 하이드록시기는 중성을 띄며, 카르복시기는 산도를 나타낸다.The polyhydroxy acid (PHA, Polyhydroxy Acids) is an organic carboxylic acid in which two or more hydroxy groups are bonded to an aliphatic or aromatic compound chain. Alpha hydroxy acid (AHA) contains a hydroxyl group at the alpha position, whereas the polyhydroxy acid (PHA) contains a hydroxyl group at various positions including the alpha position. In PHA, the hydroxy group is neutral, and the carboxy group represents acidity.
상기 폴리하이드록시애씨드로는 글루코노락톤, 락토바이오닉애씨드, 말토바이오닉애씨드로 이루어진 군에서 선택된 어느 하나 이상을 선택하여 사용할 수 있다.As the polyhydroxy acid, at least one selected from the group consisting of gluconolactone, lactobionic acid, and maltobionic acid may be used.
가장 적절하게는 글루코노락톤(Gluconolactone, C6H10O6)을 이용하는 것이 바람직할 것이다.Most appropriately, it would be preferable to use gluconolactone (C 6 H 10 O 6 ).
상기 글루코노락톤은, 하기 화학식 1의 구조를 갖는 락톤으로 피부컨디셔닝제의 일종이다. 상기 글루코노락톤은 분자 구조가 크기 때문에 피부에 빠르게 침투하지 못하여 상대적으로 적을 자극도를 보여준다. 또한, 자외선으로부터 광보호 효과를 어느 정도 가지고 있고 성분 자체적으로 습윤제로써 사용할 수도 있다. 또한, 상기 글루코노락톤은 자체적으로 상큼한 향이 나기 때문에 향료로써 사용할 수도 있다.The gluconolactone is a lactone having a structure represented by
상기 지방족 살리실릭애씨드(LHA, Lipo Hydroxy Acid)는 살리실산의 유도체로, 대표적인 성분으로는 카프릴로일살리실릭애씨드가 있다. pH5.5의 약산성을 띠기 때문에 복합성 피부의 유수분 밸런스를 안정적으로 맞춰주고, 친유 성질을 가지고 있어 지성 피부에도 좋다. 분자가 큰 물질이라 피부에 천천히 침투하므로 민감성 피부에도 제격이다.The aliphatic salicylic acid (LHA, Lipo Hydroxy Acid) is a derivative of salicylic acid, and a typical component is capryloyl salicylic acid. It has a slightly acidic pH of 5.5, so it stably adjusts the oil-moisture balance of combination skin, and it is good for oily skin because it has lipophilic properties. It is a substance with large molecules, so it penetrates the skin slowly, so it is suitable for sensitive skin.
상기 지방족 살리실릭애씨드(LHA)로는 카프릴로일살리실릭애씨드, 칼슘살리실레이트, 마그네슘살리실레이트, 엠이에이-살리실레이트, 포타슘살리실레이트, 소듐살리실릭애씨드, 티이에이-살리실레이트)과 살리실릭애씨드의 에스터(부틸옥틸살리실레이트, C12-15 알킬살리실레이트, 헥실데실살리실레이트, 아이소 세틸살리실레이트, 아이소데실살리실레이트, 에틸헥실살리실레이트, 메틸살리실레이트, 미리스틸살리실레이트, 트리데실살리실레이트로 이루어진 군에서 선택된 어느 하나 이상을 선택하여 사용할 수 있다.The aliphatic salicylic acid (LHA) includes capryloyl salicylic acid, calcium salicylate, magnesium salicylate, MEA-salicylate, potassium salicylate, sodium salicylic acid, TEA-salicylate) and esters of salicylic acid (butyloctyl salicylate, C12-15 alkyl salicylate, hexyldecyl salicylate, isocetyl salicylate, isodecyl salicylate, ethylhexyl salicylate, methyl salicylate, At least one selected from the group consisting of myristyl salicylate and tridecyl salicylate may be selected and used.
가장 적절하게는 카프릴로일살리실릭애씨드(Capryloyl Salicylic Acid, C19H20O4)를 이용하는 것이 바람직할 것이다. Most appropriately, it would be preferable to use Capryloyl Salicylic Acid (C 19 H 20 O 4 ).
상기 카프릴로일살리실릭애씨드(Capryloyl Salicylic Acid, C19H20O4)는 살리실릭애씨드와 카프릴릭애씨드의 에스터로, 피부컨디셔닝제의 일종이다. 상기 카프릴로일살리실릭애씨드는 하기 화학식 2의 구조를 갖는 것일 수 있다. 상기 카프릴로일살리실릭애씨드는 버드나무에서 추출해낸 살리실릭애씨드의 친유성 유도체로써 LHA(Lipo Hydroxy Acid) 성분이다. 상기 카프릴로일살리실릭애씨드는 방부 및 소염의 역할을 하기도 한다.The capryloyl salicylic acid (C 19 H 20 O 4 ) is an ester of salicylic acid and caprylic acid, and is a type of skin conditioning agent. The capryloyl salicylic acid may have a structure represented by Formula 2 below. The capryloyl salicylic acid is an LHA (Lipo Hydroxy Acid) component as a lipophilic derivative of salicylic acid extracted from willow. The capryloyl salicylic acid also acts as an antiseptic and anti-inflammatory.
한편, 상기 소듐하이알루로네이트크로스폴리머(Sodium Hyaluronate Crosspolymer)는 비닐설폰과 가교된 하이알루로닉애씨드 중합체의 소듐염으로, 피부보습제, 피부컨디셔닝제로 이용되는 성분이다. 상기 소듐하이알루로네이트크로스폴리머는 EWG그린등급의 1급 성분으로 발암, 독성, 알레르기 유발 확률이 거의 없는 안전한 성분이다. 상기 소듐하이알루로네이트크로스폴리머는 히알루론산 하이드로겔을 형성하는 수용성 파우더이며, 다당류의 일종으로 백색분말 형태를 띄고 있다. 상기 소듐하이알루로네이트크로스폴리머는 보습능력이 우수하여, 화장품 내에 보습 효과가 매우 우수하다. On the other hand, the sodium hyaluronate crosspolymer (Sodium Hyaluronate Crosspolymer) is a sodium salt of a hyaluronic acid polymer crosslinked with vinylsulfone, and is a component used as a skin moisturizer and skin conditioning agent. The sodium hyaluronate crosspolymer is a first-class component of the EWG green grade and is a safe component with little possibility of causing carcinogenesis, toxicity, or allergy. The sodium hyaluronate crosspolymer is a water-soluble powder that forms a hyaluronic acid hydrogel, and is a kind of polysaccharide and has a white powder form. The sodium hyaluronate crosspolymer has excellent moisturizing ability, and thus has a very excellent moisturizing effect in cosmetics.
본 발명에 따른 화장료 조성물은 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머의 혼합에 따라 각질제거효과와 보습효과에 대한 예기치 못한 우수한 효과를 발견하였기에, 이에 대한 내용을 기재한다.The cosmetic composition according to the present invention has unexpectedly excellent effects on exfoliation and moisturizing effects according to the mixing of polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer. , write about it.
본 발명에 따른 각질제거효과와 보습효과를 동시에 갖는 화장료 조성물에 있어서, 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머는 각각 0.001 ~ 10.0중량%로 포함될 수 있다.In the cosmetic composition having both exfoliation and moisturizing effects according to the present invention, the polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer are each 0.001 to 10.0% by weight. can be included
한편, 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머는 각각 0.001 ~ 10.0 : 0.001 ~ 10.0 : 0.001 ~ 10.0의 중량비로 혼합되는 것일 수 있다.Meanwhile, the polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer may be mixed in a weight ratio of 0.001 to 10.0: 0.001 to 10.0: 0.001 to 10.0, respectively.
상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머는 70 ~ 90℃의 온도에서 150rpm ~ 250rpm의 속도록 교반하여 혼합된 것을 이용하는 것일 수 있다.The polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer may be mixed by stirring at a speed of 150 rpm to 250 rpm at a temperature of 70 to 90 ° C.
본 발명에 따른 각질제거효과와 보습효과를 동시에 갖는 화장료 조성물은 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머의 혼합물을 포함하며, 그 외에 추가적인 다른 성분들을 포함하여, 로션, 크림, 젤, 수용성 리퀴드, 수중유(O/W)형 화장품, 유중수(W/O)형 화장품 및 실리콘중수(W/Si)형 화장품, 용액, 현탁액, 유탁액, 페이스트, 파우더, 비누, 계면활성제-함유 클린징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 스프레이 및 마스크 시트 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 로션, 바디로션 등과 같은 유액, 영양크림, 수분 크림, 아이 크림 등과 같은 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더 중 어느 하나의 제형을 갖는 화장료 조성물로 제형화 될 수 있을 것이다.The cosmetic composition having both an exfoliating effect and a moisturizing effect according to the present invention includes a mixture of polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer, and in addition, additional other Including ingredients, lotions, creams, gels, water-soluble liquids, oil-in-water (O/W) cosmetics, water-in-oil (W/O) cosmetics and water-in-silicone (W/Si) cosmetics, solutions, suspensions, emulsions , Pastes, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, sprays and mask sheets may be formulated, but are not limited thereto. More specifically, lotion such as softening lotion or nourishing lotion, emulsion such as lotion, body lotion, etc., cream such as nourishing cream, moisture cream, eye cream, essence, cosmetic ointment, spray, gel, pack, sunscreen, makeup base , Liquid type, solid type, or spray type foundation, such as powder, will be able to be formulated as a cosmetic composition having any one formulation.
예를 들어, 로션 형상으로 제조될 경우, 크림 형상에 맞는 적절한 성분을 고려하여 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머의 혼합물과 함께 제형화하는 것이 바람직할 것이다.For example, when it is prepared in the form of a lotion, it is formulated with a mixture of polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer in consideration of appropriate ingredients suitable for the cream form. It would be preferable to
예를 들어, 크림 형상으로 제조될 경우, 겔 형상에 맞는 적절한 성분을 고려하여 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머의 혼합물과 함께 제형화하는 것이 바람직할 것이다.For example, when prepared in a cream form, it is formulated with a mixture of polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer in consideration of appropriate ingredients suitable for the gel form. It would be preferable to
예를 들어, 젤 형상으로 제조될 경우, 로션 형상에 맞는 적절한 성분을 고려하여 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머의 혼합물과 함께 제형화하는 것이 바람직할 것이다.For example, when prepared in a gel form, it is formulated with a mixture of polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer in consideration of appropriate ingredients suitable for the lotion form. It would be preferable to
한편, 본 발명에 따른 화장료 조성물은 상기 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 지방족 살리실릭애씨드(LHA)는 카프릴로일살리실릭애씨드 외에, 용매, 계면활성제, 폴리올, 점증제, 용해제, 착색제, 색소, 보존제, 안정화제, 에몰리언트제, 자외선 흡수제, 방부제, 살균제, 유화제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 정제수, 분산제, 충전제, 감미료, 비타민, 자유-라디칼 스케빈저, 금속이온 봉쇄제, 냉감제, 제한제, 수산화염 중 어느 하나 이상의 첨가제를 더 포함할 수 있다. 상기 보존제 등의 추가 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정하여 사용할 수 있을 것이다.On the other hand, in the cosmetic composition according to the present invention, the polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and aliphatic salicylic acid (LHA), in addition to capryloyl salicylic acid, solvent, surfactant, polyol, thickener agents, solubilizers, colorants, pigments, preservatives, stabilizers, emollients, UV absorbers, preservatives, bactericides, emulsifiers, antioxidants, pH adjusters, organic and inorganic pigments, flavors, purified water, dispersants, fillers, sweeteners, vitamins, free- It may further include any one or more additives of a radical scavenger, a metal ion sequestering agent, a cooling agent, an antiperspirant, and a hydroxide salt. The mixing amount of the additional components such as the preservative may be easily selected and used by those skilled in the art within a range that does not impair the objects and effects of the present invention.
또한, 상기 계면활성제는 합성 계면활성제 또는 천연 계면활성제를 단독 또는 2종 이상 혼용해서 사용할 수 있다. 구체적으로 상기 계면활성제는 음이온성 계면활성제, 양이온성 계면활성제, 양쪽성 계면활성제 또는 비이온성 계면활성제 등이 사용될 수 있다. 상기 계면활성제 중 음이온계 계면활성제는 구체적으로 암모늄 라우릴설포석시네이트, 암모늄 라우릴 설페이트, 소듐코코일이세티오네이트, 소듐라우로일메틸이세티오네이트, 소듐라우릴설페이트, 트리에탄올아민 라우릴설페이트, 소듐라우릴에테르설페이트(에틸렌옥사이드 1～3개) 등이 될 수 있다. 계면활성제 중 비이온성 계면활성제는 구체적으로 폴리옥시에틸렌알킬에테르, 폴리옥시에틸렌지방산에스테르, 폴리옥시에틸렌, 경화 피마자유 유도체, 지방산 다이에탄올아미드, 글리세릴스테아레이트 등이 될 수 있다. 계면활성제 중 양이온성 계면활성제는 구체적으로 3급 지방족 아민염, 알킬트리메틸암모늄클로라이드, 다이알킬다이메틸암모늄클로라이드 등이 될 수 있다. 계면활성제 중 양쪽성 계면활성제는 구체적으로 베타인, 아미드베타인형, 설포베타인형, 스테아르트리모늄클로라이드 등이 될 수 있다. 한편, 계면활성제로는 세테아릴올리베이트, 비즈왁스, 폴리글리세린 지방산에스테르(Polyglycerin Fatty Acid Ester), 폴리글리세릴-3메틸글루코오스다이스테아레이트(Polyglyceryl-3 Methyglucose Distearate), 올레스-10(Oleth-10), 세테스-10(Ceteth-10), 코카마이드엠이에이(Cocamide MEA) 및 폴리옥시에틸렌소르비탄 모노올레이트(Tween80) 등을 이용할 수도 있다.In addition, the surfactant may be used alone or in combination of two or more synthetic surfactants or natural surfactants. Specifically, anionic surfactants, cationic surfactants, amphoteric surfactants, or nonionic surfactants may be used as the surfactant. Among the surfactants, the anionic surfactants are specifically ammonium lauryl sulfosuccinate, ammonium lauryl sulfate, sodium cocoyl isethionate, sodium lauroylmethyl isethionate, sodium lauryl sulfate, triethanolamine It can be uryl sulfate, sodium lauryl ether sulfate (1-3 ethylene oxide), etc. Among the surfactants, the nonionic surfactant may specifically be polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene, hydrogenated castor oil derivative, fatty acid diethanolamide, glyceryl stearate, and the like. Among the surfactants, the cationic surfactant may specifically be a tertiary aliphatic amine salt, alkyltrimethylammonium chloride, dialkyldimethylammonium chloride, or the like. Among the surfactants, the amphoteric surfactant may specifically be betaine, amide betaine type, sulfobetaine type, steartrimonium chloride, and the like. On the other hand, surfactants include cetearyl olive, beeswax, polyglycerin fatty acid ester, polyglyceryl-3 methylglucose distearate, and Oleth-10. -10), Ceteth-10, Cocamide MEA, and polyoxyethylene sorbitan monooleate (Tween80) may also be used.
또한, 상기 폴리올은 글리세린, 다이프로필렌글라이콜, 부틸렌글라이콜, 펜틸렌글라이콜, 메틸프로판다이올, 솔비톨, 다이글리세린, 에리스리톨, 펜타에리스리톨, 폴리부틸렌글라이콜-10, 폴리글리세린-3, 폴리글리세린-4, 폴리글리세린-6, 폴리글리세린-10, 폴리글리세린-20, 폴리글리세린-40, 솔베스-5, 솔베스-6, 솔베스-20, 솔베스-30, 솔베스-40, 이노시톨, 말티톨, 말토스, 만난, 만니톨, 만노스, 락티톨, 락토스, 다이하이드록시프로필 PG-글루코사이드, 다이티아옥테인다이올, 프룩토오스, 글루카민, 메틸글루카민, 글루코스, 1,6-헥산디올, 메틸글루세스-10, 메틸글루세스-20, 오조니즈드글리세린, 피탄트리올, 치오글리세린, 트레이톨, 트리메틸올프로판, 자일리톨로 이루어진 군에서 어느 하나 이상을 선택하여 사용할 수 있을 것이다.In addition, the polyol is glycerin, dipropylene glycol, butylene glycol, pentylene glycol, methyl propanediol, sorbitol, diglycerin, erythritol, pentaerythritol, polybutylene glycol-10, polyglycerin-3 , Polyglycerin-4, Polyglycerin-6, Polyglycerin-10, Polyglycerin-20, Polyglycerin-40, Solves-5, Solves-6, Solves-20, Solves-30, Solves-40 , inositol, maltitol, maltose, mannan, mannitol, mannose, lactitol, lactose, dihydroxypropyl PG-glucoside, dithiaoctanediol, fructose, glucamine, methylglucamine, glucose, 1,6 -Any one or more selected from the group consisting of hexanediol, methylgluses-10, methylgluses-20, ozonized glycerin, phytantriol, thioglycerin, threitol, trimethylolpropane, and xylitol may be used. .
이와 같이, 통상적으로 알려진 첨가제류가 추가로 사용될 수 있을 것이며, 이는 통상의 기술자의 선택에 맡길 수 있을 것이다. 본 발명에서는 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 구성성분으로 포함하는 모든 조성물에 대한 권리를 주장하며, 보다 구체적으로는 글루코노락톤, 카프릴로일살리실릭애씨드 및, 소듐하이알루로네이트크로스폴리머를 포함하는 모든 조성물에 대한 권리를 주장하고자 하는 것이며, 첨가제류는 어느 종류의 첨가제가 들어와도 무방하다.As such, commonly known additives may additionally be used, which may be left to the skilled person's choice. The present invention claims the right to all compositions containing polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer as components, and more specifically, gluconolactone, carf It is intended to claim the rights to all compositions containing liloyl salicylic acid and sodium hyaluronate crosspolymer, and additives may be of any kind.
이하, 하기 실시예, 비교예 및 실험예를 통하여, 본 발명에 따른 화장료 조성물이 갖는 효과에 대하여 자세히 알아본다.Hereinafter, through the following Examples, Comparative Examples and Experimental Examples, the effects of the cosmetic composition according to the present invention will be studied in detail.
실시예Example 1 내지 7 및 1 to 7 and 비교예comparative example 1 내지 6. 1 to 6. 글루코노락톤Gluconolactone (( PHAPHAs ), ), 카프릴로일살리실릭애씨드Capryloyl Salicylic Acid (LHA) 및, (LHA) and, 소듐하이알루로네이트크로스폴리머의sodium hyaluronate crosspolymer 혼합물을 포함하는 실험용 조성물의 제조 Preparation of Experimental Compositions Containing Admixtures
하기 제조 방법에 따라 실시예 1의 실험용 조성물을 제조하였다.The experimental composition of Example 1 was prepared according to the following preparation method.
글루코노락톤(PHA), 카프릴로일살리실릭애씨드(LHA), 소듐하이알루로네이트크로스폴리머, 세틸에틸헥사노에이트, 세테아릴올리베이트 및 정제수를 하기 표 1의 함량으로 포함하여, 80℃의 온도에서 200rpm의 속도로 교반하여 혼합물을 제조하였다.Gluconolactone (PHA), capryloyl salicylic acid (LHA), sodium hyaluronate crosspolymer, cetylethylhexanoate, cetearylolivate and purified water in the contents shown in Table 1 below, 80 ℃ A mixture was prepared by stirring at a temperature of 200 rpm.
비교예comparative example 7. 7. 글루코노락톤Gluconolactone (( PHAPHAs ) 및 ) and 카프릴로일살리실릭애씨드(LHA)의capryloyl salicylic acid (LHA) 혼합물을 포함하는 실험용 조성물의 제조 Preparation of Experimental Compositions Containing Admixtures
하기 제조 방법에 따라 비교예 7의 실험용 조성물을 제조하였다.An experimental composition of Comparative Example 7 was prepared according to the following preparation method.
글루코노락톤(PHA) 7.5 중량%, 카프릴로일살리실릭애씨드(LHA) 7.5 중량%, 세틸에틸헥사노에이트 15.0 중량%, 세테아릴올리베이트 1.0중량%, 및 잔량으로 정제수를 포함하여, 80℃의 온도에서 200rpm의 속도로 교반하여 혼합물을 제조하였다.7.5% by weight of gluconolactone (PHA), 7.5% by weight of capryloyl salicylic acid (LHA), 15.0% by weight of cetylethylhexanoate, 1.0% by weight of cetearyl olive, and the remainder including purified water, 80 A mixture was prepared by stirring at a temperature of °C and a speed of 200 rpm.
비교예comparative example 8. 8. 글루코노락톤Gluconolactone (( PHAPHAs ) 및 ) and 소듐하이알루로네이트크로스폴리머의sodium hyaluronate crosspolymer 혼합물을 포함하는 실험용 조성물의 제조 Preparation of Experimental Compositions Containing Admixtures
하기 제조 방법에 따라 비교예 8의 실험용 조성물을 제조하였다.An experimental composition of Comparative Example 8 was prepared according to the following preparation method.
글루코노락톤(PHA) 7.5 중량%, 소듐하이알루로네이트크로스폴리머 7.5 중량%, 세틸에틸헥사노에이트 15.0 중량%, 세테아릴올리베이트 1.0중량% 및, 잔량으로 정제수를 포함하여, 80℃의 온도에서 200rpm의 속도로 교반하여 혼합물을 제조하였다.Gluconolactone (PHA) 7.5% by weight, sodium hyaluronate crosspolymer 7.5% by weight, cetylethylhexanoate 15.0% by weight, cetearyl olive 1.0% by weight, and the balance including purified water, at 80 ° C. A mixture was prepared by stirring at a speed of 200 rpm at a temperature.
비교예comparative example 9. 9. 카프릴로일살리실릭애씨드Capryloyl Salicylic Acid (( LHALHA ) 및 ) and 소듐하이알루로네이트크로스폴리머의sodium hyaluronate crosspolymer 혼합물을 포함하는 실험용 조성물의 제조 Preparation of Experimental Compositions Containing Admixtures
하기 제조 방법에 따라 비교예 9의 실험용 조성물을 제조하였다.An experimental composition of Comparative Example 9 was prepared according to the following preparation method.
카프릴로일살리실릭애씨드(LHA) 7.5 중량%, 소듐하이알루로네이트크로스폴리머 7.5 중량% 세틸에틸헥사노에이트 15.0 중량%, 세테아릴올리베이트 1.0중량% 및, 잔량으로 정제수를 포함하여, 80℃의 온도에서 200rpm의 속도로 교반하여 혼합물을 제조하였다.7.5% by weight of capryloyl salicylic acid (LHA), 7.5% by weight of sodium hyaluronate crosspolymer, 15.0% by weight of cetylethylhexanoate, 1.0% by weight of cetearyl olive, and 80% by weight of purified water A mixture was prepared by stirring at a temperature of °C and a speed of 200 rpm.
비교예comparative example 10. 10. 글루코노락톤Gluconolactone (( PHAPHAs ) 만을 단독으로 포함하는 실험용 조성물의 제조) Preparation of an experimental composition containing only
하기 제조 방법에 따라 비교예 10의 실험용 조성물을 제조하였다.An experimental composition of Comparative Example 10 was prepared according to the following preparation method.
글루코노락톤(PHA) 15.0 중량%, 세틸에틸헥사노에이트 15.0 중량%, 세테아릴올리베이트 1.0중량% 및, 잔량으로 정제수를 포함하여, 80℃의 온도에서 200rpm의 속도로 교반하여 혼합물을 제조하였다.15.0% by weight of gluconolactone (PHA), 15.0% by weight of cetylethylhexanoate, 1.0% by weight of cetearylolivate, and the remaining amount of purified water, including stirring at a temperature of 80 ° C. at a speed of 200 rpm to prepare a mixture did
비교예comparative example 11. 11. 카프릴로일살리실릭애씨드Capryloyl Salicylic Acid (( LHALHA ) 만을 단독으로 포함하는 실험용 조성물의 제조) Preparation of an experimental composition containing only
하기 제조 방법에 따라 비교예 11의 실험용 조성물을 제조하였다.An experimental composition of Comparative Example 11 was prepared according to the following preparation method.
카프릴로일살리실릭애씨드(LHA) 15.0 중량%, 세틸에틸헥사노에이트 15.0 중량%, 세테아릴올리베이트 1.0중량% 및, 잔량으로 정제수를 포함하여, 80℃의 온도에서 200rpm의 속도로 교반하여 혼합물을 제조하였다.15.0% by weight of capryloyl salicylic acid (LHA), 15.0% by weight of cetylethylhexanoate, 1.0% by weight of cetearylolivate, and the remaining amount of purified water, including stirring at a speed of 200 rpm at a temperature of 80 ° C. A mixture was prepared.
비교예comparative example 12. 12. 소듐하이알루로네이트크로스폴리머Sodium Hyaluronate Crosspolymer 만을 단독으로 포함하는 실험용 조성물의 제조 Preparation of an experimental composition containing only
하기 제조 방법에 따라 비교예 12의 실험용 조성물을 제조하였다.An experimental composition of Comparative Example 12 was prepared according to the following preparation method.
소듐하이알루로네이트크로스폴리머 15.0 중량%, 세틸에틸헥사노에이트 15.0 중량%, 세테아릴올리베이트 1.0중량% 및, 잔량으로 정제수를 포함하여, 80℃의 온도에서 200rpm의 속도로 교반하여 혼합물을 제조하였다.15.0% by weight of sodium hyaluronate crosspolymer, 15.0% by weight of cetylethylhexanoate, 1.0% by weight of cetearyl olivate, and the remaining amount of purified water, and stirred at a speed of 200 rpm at a temperature of 80 ° C to form a mixture manufactured.
실험예Experimental example 1. 각질 제거 효과 확인 1. Check the exfoliation effect
실시예 1 내지 7 및 비교예 1 내지 12에 대해 각질 제거 효과를 확인하였다. 실험은 공지된 방법을 이용하여 진행하였다.The exfoliation effect of Examples 1 to 7 and Comparative Examples 1 to 12 was confirmed. The experiment was conducted using a known method.
실시예 1 내지 7 및 비교예 1 내지 12에 대한 각질 제거 효과 측정은 온도 24±1℃, 습도 55±10℃ 환경에서 진행하였다. 실험 전 각질량을 측정하였고 무작위로 대조군(Control) 3명, 실시예 1 내지 7 및 비교예 1 내지 12의 조성물을 각각 3명으로 하여 측정하였다.The measurement of the exfoliation effect for Examples 1 to 7 and Comparative Examples 1 to 12 was conducted in an environment of a temperature of 24 ± 1 ° C and a humidity of 55 ± 10 ° C. Before the experiment, the amount of keratin was measured, and the composition of Examples 1 to 7 and Comparative Examples 1 to 12 was randomly measured by 3 control subjects and 3 subjects respectively.
피부표피층의 변화를 관찰하기 위하여, 피부 진단기를 통해 실시예 1 내지 7 및 비교예 1 내지 12를 이용한 클린징 후의 변화를 관찰하여 비교하였다. 클린징 이전과, 실시예 1 내지 7 및 비교예 1 내지 12를 이용한 클린징 10분 후에 피부진단기를 사용하여 각질량을 측정하고, 2주, 4주 동안 꾸준히 사용하게 한 후, 피부진단기를 사용하여 각질량을 측정하였다. 각질량 측정은 왼쪽 U-zone인 관골근 아래쪽에 각질테이프(봄텍사, 서울, 한국)를 붙였다가 떼어서 피부진단기의 SD 프로그램으로 측정하였다. 하기 표 2에 각질 인덱스의 변화를 정리하였다. 클린징 직전의 각질량을 100%로 기준하여 10분 후, 2주 후, 4주 후의 각질량을 백분율로 나타내었다.In order to observe changes in the skin epidermal layer, changes after cleansing using Examples 1 to 7 and Comparative Examples 1 to 12 were observed and compared through a skin diagnostic device. Before cleansing and 10 minutes after cleansing using Examples 1 to 7 and Comparative Examples 1 to 12, the amount of dead skin cells was measured using a skin tester, and after being used continuously for 2 weeks and 4 weeks, each skin tester was used to measure the amount of dead skin cells. Mass was measured. The amount of keratin was measured by attaching a keratin tape (Bomtech, Seoul, Korea) to the lower part of the acetabular muscle, which is the left U-zone, and then peeling it off and using the SD program of the skin diagnostic device. Changes in the keratin index are summarized in Table 2 below. Based on the amount of dead skin immediately before cleansing as 100%, the amount of dead skin after 10 minutes, 2 weeks, and 4 weeks was expressed as a percentage.
그 결과, 상기 표 2에 나타난 바와 같이, 실시예 1 내지 7의 경우, 클린징 전의 각질량에 비해, 10분, 2주, 4주 후의 각질량이 현저히 줄어드는 것을 확인할 수 있었다. 반면, 비교예 1 내지 6의 경우 실시예 1 내지 7에 비해서는 각질량의 감소폭이 적었으며, 비교예 7 내지 12의 경우에는 그보다 더 낮은 감질 감소량을 보이는 것을 확인할 수 있었다.As a result, as shown in Table 2, in the case of Examples 1 to 7, it was confirmed that the amount of dead skin cells after 10 minutes, 2 weeks, and 4 weeks was significantly reduced compared to the amount of dead skin cells before cleansing. On the other hand, in Comparative Examples 1 to 6, the decrease in keratin amount was less than in Examples 1 to 7, and in Comparative Examples 7 to 12, it was confirmed that a lower amount of tannin reduction was shown.
실험예Experimental example 2. 각질 현미경 촬영 2. Keratin microscopy
각질에 대한 현미경 촬영은 왼쪽 U-zone인 관골근 아래쪽에 각질테이프(봄텍사, 서울, 한국)를 붙였다가 떼어서 수행되었다. 잔여 각질에 대해 자세하게 확인할 수 있도록 형광 염색을 수행하였다. Microscopic imaging of keratin was performed by attaching and peeling keratin tape (Bomtech, Seoul, Korea) to the lower part of the acetabular muscle, which is the left U-zone. Fluorescence staining was performed so that residual keratin could be identified in detail.
피시험자를 9명 선발하여, 비교예 3, 실시예 4, 비교예 6, 비교예 7, 비교예 8, 비교예 9, 비교예 10, 비교예 11, 비교예 12를 대표 실험군로 선정하여 클린징에 사용하게 하였으며, 사용 전, 10분 경과, 2주 경과, 4주경과 각각 다른 부위의 피부로부터 테이프를 이용해 떼어난 각질 표본을, 현미경을 이용해 촬영하여 도 2에 도시하였다. Nine test subjects were selected, and Comparative Example 3, Example 4, Comparative Example 6, Comparative Example 7, Comparative Example 8, Comparative Example 9, Comparative Example 10, Comparative Example 11, and Comparative Example 12 were selected as representative experimental groups for cleansing. Before use, after 10 minutes, after 2 weeks, and after 4 weeks, keratin specimens removed using tape from different parts of the skin were photographed using a microscope and shown in FIG. 2.
도 2에서 푸른색이 많이 나타날수록 각질이 높게 분포하는 것을 의미한다. 도 2에 도시된 바와 같이, 실시예 4의 경우 4주 후에는 각질이 거의 나타나지 않았다. 반면에, 비교예의 경우 푸른색이 높게 나타나 각질이 완벽히 제거되지는 않았음을 확인할 수 있다.In FIG. 2, the higher the blue color, the higher the distribution of keratin. As shown in FIG. 2, in the case of Example 4, almost no keratin appeared after 4 weeks. On the other hand, in the case of Comparative Example, it can be confirmed that the blue color was high, and the dead skin cells were not completely removed.
실험예 3. 피부 보습 효과 확인Experimental Example 3. Confirmation of skin moisturizing effect
실시예 1 내지 7 및 비교예 1 내지 12의 조성물에 대해서, 실험 결과에 영향을 줄 만한 피부질환이 없는 22∼33세의 남녀 20(남자 5명, 여자 15명)을 대상으로 실험하였으며, 각 대상들은 시료 적용 전 실험부위를 물로 세정한 후 30분 동안 외적 환경에 적응하게 하였다. 실험 환경조건은 실내온도 22∼24℃, 실내습도 45∼50%로 유지시킨 동일한 장소에서 시행하였다. 시료 도포 전 Corneometer를 이용하여 수분량을 우선 측정하였다. 시료를 각각 10uL씩 상완 내측 2×2㎠로 도포하고 1분간 건조했다. 그 후 각 도포부위에 정제수 20uL씩 도포하고, 킴와이프로 수분을 닦아내고 15분 후 도포부위의 피부표면을 Corneometer(㎝ 825)로 측정하여 하기 표 3에 나타내었다. 단위는 Corneometer value(Cv)로 나타냈다.The compositions of Examples 1 to 7 and Comparative Examples 1 to 12 were tested on 20 male and female subjects (5 males and 15 females) between the ages of 22 and 33 who did not have skin diseases that could affect the test results, and each The subjects were allowed to adapt to the external environment for 30 minutes after washing the experimental site with water before applying the sample. Experimental environmental conditions were conducted in the same place where the room temperature was maintained at 22∼24℃ and the indoor humidity was maintained at 45∼50%. Before applying the sample, the moisture content was first measured using a corneometer. Each sample was applied to 2 × 2 cm 2 on the inside of the upper arm at a rate of 10 uL and dried for 1 minute. After that, 20uL of purified water was applied to each application site, and the moisture was wiped off with a Kimwipe. After 15 minutes, the skin surface of the application site was measured with a Corneometer (cm 825) and shown in Table 3 below. The unit was expressed as Corneometer value (Cv).
그 결과, 상기 표3에 나타난 바와 같이, 실시예 1 내지 7의 경우, 시료 도포 후 15 분 경과 후에도 높은 수분량을 유지하는 것을 확인할 수 있었다. 반면, 비교예 1 내지 6의 경우 실시예 1 내지 7에 비해서는 수분량이 적게 나타났으며, 비교예 7 내지 12의 경우에는 그보다 더 낮은 수분량을 보이는 것을 확인할 수 있었다.As a result, as shown in Table 3, in the case of Examples 1 to 7, it was confirmed that a high moisture content was maintained even after 15 minutes after application of the sample. On the other hand, in the case of Comparative Examples 1 to 6, the moisture content was less than that of Examples 1 to 7, and in the case of Comparative Examples 7 to 12, it was confirmed that the moisture content was lower than that.
상기 실시예, 비교예 및 실험예를 통해 확인한 바와 같이, 본 발명에 따른 화장료 조성물은 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 포함하여, 각질제거효과 및 보습효과를 가짐을 확인할 수 있었다.As confirmed through the above Examples, Comparative Examples and Experimental Examples, the cosmetic composition according to the present invention includes polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer, including keratin It was confirmed that it had a removal effect and a moisturizing effect.
우선, 실험예 1을 통해, 본 발명에 따른 화장료 조성물은 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 포함하여, 예기치 못한 효과가 나타나, 각각의 구성성분이 개별로 포함될 때에 비해, 각질량이 현저히 줄어들게 하는 것을 확인할 수 있었다.First, through Experimental Example 1, the cosmetic composition according to the present invention includes polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer, showing unexpected effects, each It was confirmed that the amount of keratin was significantly reduced compared to when the components were included individually.
또한, 실험예 2를 통해, 본 발명에 따른 화장료 조성물은 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 포함하여, 예기치 못한 효과가 나타나, 각각의 구성성분이 개별로 포함될 때에 비해, 각질이 거의 나타나지 않은 모습을 확인할 수 있었다.In addition, through Experimental Example 2, the cosmetic composition according to the present invention includes polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer, showing unexpected effects, each It was confirmed that almost no keratin appeared compared to when the components were included individually.
한편, 실험예 3을 통해, 본 발명에 따른 화장료 조성물은 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 포함하여, 예기치 못한 효과가 나타나, 각각의 구성성분이 개별로 포함될 때에 비해, 보습효과가 우수함을 확인할 수 있었다.On the other hand, through Experimental Example 3, the cosmetic composition according to the present invention includes polyhydroxy acid (PHA), aliphatic salicylic acid (LHA) and sodium hyaluronate crosspolymer, showing unexpected effects, each It was confirmed that the moisturizing effect was excellent compared to when the components were included individually.
이에, 본 발명은 폴리하이드록시애씨드(PHA), 지방족 살리실릭애씨드(LHA) 및 소듐하이알루로네이트크로스폴리머를 포함하여, 각질제거효과와 보습효과를 동시에 갖는 신규한 화장료 조성물로써, 각질제거효과와 보습효과를 동시에 갖는 화장료 조성물을 개발하였음을 명시한다.Accordingly, the present invention is a novel cosmetic composition including polyhydroxy acid (PHA), aliphatic salicylic acid (LHA), and sodium hyaluronate crosspolymer, which has both an exfoliating effect and a moisturizing effect, and has an exfoliating effect. It is specified that a cosmetic composition having both moisturizing and moisturizing effects has been developed.
본 발명을 첨부된 도면과 함께 설명하였으나, 이는 본 발명의 요지를 포함하는 다양한 실시 형태 중의 하나의 실시 예에 불과하며, 당 업계에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 하는 데에 그 목적이 있는 것으로, 본 발명은 상기 설명된 실시예에만 국한되는 것이 아님은 명확하다. 따라서, 본 발명의 보호범위는 하기의 청구범위에 의해 해석되어야 하며, 본 발명의 요지를 벗어나지 않는 범위 내에서 변경, 치환, 대체 등에 의해 그와 동등한 범위 내에 있는 모든 기술 사상은 본 발명의 권리에 포함될 것이다. 또한, 도면의 일부 구성은 구성을 보다 명확하게 설명하기 위한 것으로 실제보다 과장되거나 축소되어 제공되는 것임을 명확히 한다.Although the present invention has been described with the accompanying drawings, this is only one example of various embodiments including the gist of the present invention, and is intended to be easily practiced by those skilled in the art. As an object, it is clear that the present invention is not limited to the embodiments described above. Therefore, the protection scope of the present invention should be interpreted by the following claims, and all technical ideas within the equivalent range by change, substitution, substitution, etc. within the scope of the present invention do not depart from the scope of the present invention. will be included In addition, it is clear that some configurations in the drawings are provided exaggerated or reduced than the actual configuration to more clearly explain the configuration.
Claims (5)
상기 혼합물 외에, 계면활성제, 폴리올, 점증제, 용해제, 착색제, 색소, 보존제, 안정화제, 에몰리언트제, 자외선 흡수제, 방부제, 살균제, 유화제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 정제수, 분산제, 충전제, 감미료, 비타민, 자유-라디칼 스케빈저, 금속이온 봉쇄제, 냉감제, 제한제, 수산화염 중 어느 하나 이상의 첨가제를 더 포함하여,
로션, 크림, 젤, 수용성 리퀴드, 수중유(O/W)형 화장품, 유중수(W/O)형 화장품 및 실리콘중수(W/Si)형 화장품, 용액, 현탁액, 유탁액, 페이스트, 파우더, 비누, 계면활성제-함유 클린징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 스프레이 또는 마스크시트 중 어느 하나의 제형으로 제형화 되며, 각질제거효과 및 보습효과를 갖는 것을 특징으로 하는 화장료 조성물.
0.001 to 10.0% by weight of gluconolactone (PHA); 0.001 to 10.0% by weight of capryloyl salicylic acid (LHA); 0.001 to 10.0% by weight of sodium hyaluronate crosspolymer; and 15.0% by weight of cetylethylhexanoate; It contains a mixture of 1.0% by weight of cetearyl olivate and the remaining amount of purified water,
In addition to the above mixtures, surfactants, polyols, thickeners, solubilizers, colorants, pigments, preservatives, stabilizers, emollients, ultraviolet absorbers, preservatives, bactericides, emulsifiers, antioxidants, pH adjusters, organic and inorganic pigments, fragrances, purified water, Further comprising any one or more additives among dispersants, fillers, sweeteners, vitamins, free-radical scavengers, metal ion sequestering agents, cooling agents, antiperspirants, and hydroxides,
Lotions, creams, gels, water-soluble liquids, oil-in-water (O/W) cosmetics, water-in-oil (W/O) cosmetics and water-in-silicone (W/Si) cosmetics, solutions, suspensions, emulsions, pastes, powders, Soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray or mask sheet formulated in any one formulation, characterized in that it has an exfoliating effect and moisturizing effect A cosmetic composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220006017A KR102472483B1 (en) | 2022-01-14 | 2022-01-14 | Cosmetic composition having exfoliating effect and moisturizing effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220006017A KR102472483B1 (en) | 2022-01-14 | 2022-01-14 | Cosmetic composition having exfoliating effect and moisturizing effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102472483B1 true KR102472483B1 (en) | 2022-12-01 |
Family
ID=84440752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220006017A KR102472483B1 (en) | 2022-01-14 | 2022-01-14 | Cosmetic composition having exfoliating effect and moisturizing effect |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102472483B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117137844A (en) * | 2023-09-28 | 2023-12-01 | 广东领康日用品有限公司 | Acne-removing and oil-controlling skin care composition and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101388052B1 (en) | 2012-02-03 | 2014-04-25 | 주식회사 씨앤피코스메틱스 | Composition for cosmetics comprising gluconolactone and lactobionic acid for skin exfoliation, skin whitening or improvement of skin tone |
| KR101987559B1 (en) * | 2017-12-11 | 2019-06-10 | 주식회사 씨앤피코스메틱스 | A cosmetic composition having excellent skin moisturizing effect |
| KR102089731B1 (en) * | 2019-08-13 | 2020-03-17 | 주식회사 도나 | One-step bubble cleansing pad |
| KR102227355B1 (en) * | 2020-08-03 | 2021-03-11 | 민디선 민 | Complex cosmetic composition for non-irritating weak acid exfoliation and epithelial cell nutrition |
| KR102351202B1 (en) * | 2021-11-05 | 2022-01-14 | 주식회사 레몬앰앤피 | Peeling cosmetic composition containing acacia honey-derived lapaglowacid, which removes hypoallergenic dead skin cells, improves skin tone-up effect, and improves oil-water moisture balance, and method for manufacturing the same |
-
2022
- 2022-01-14 KR KR1020220006017A patent/KR102472483B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101388052B1 (en) | 2012-02-03 | 2014-04-25 | 주식회사 씨앤피코스메틱스 | Composition for cosmetics comprising gluconolactone and lactobionic acid for skin exfoliation, skin whitening or improvement of skin tone |
| KR101987559B1 (en) * | 2017-12-11 | 2019-06-10 | 주식회사 씨앤피코스메틱스 | A cosmetic composition having excellent skin moisturizing effect |
| KR102089731B1 (en) * | 2019-08-13 | 2020-03-17 | 주식회사 도나 | One-step bubble cleansing pad |
| KR102227355B1 (en) * | 2020-08-03 | 2021-03-11 | 민디선 민 | Complex cosmetic composition for non-irritating weak acid exfoliation and epithelial cell nutrition |
| KR102351202B1 (en) * | 2021-11-05 | 2022-01-14 | 주식회사 레몬앰앤피 | Peeling cosmetic composition containing acacia honey-derived lapaglowacid, which removes hypoallergenic dead skin cells, improves skin tone-up effect, and improves oil-water moisture balance, and method for manufacturing the same |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117137844A (en) * | 2023-09-28 | 2023-12-01 | 广东领康日用品有限公司 | Acne-removing and oil-controlling skin care composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6843863B2 (en) | Compositions containing at least two fatty acid esters of (poly) glycerol, and their use in cosmetics | |
| US7381436B2 (en) | Cosmetic composition in particular with anti-ageing activity comprising an extract of Aframomum angustifolium or longoza plant | |
| CH695085A5 (en) | Formulations for care of the skin after laser treatment and / or chemical peels, and use of formulations. | |
| EA023290B1 (en) | Method of treating skin and topical composition for rejuvenating, replenishing and firming skin during sleep | |
| WO2011001633A1 (en) | External preparation for the skin | |
| JP6313961B2 (en) | Oil-in-water emulsion composition | |
| CN106860088A (en) | A kind of whitening is dispelled scar skin care item and preparation method thereof | |
| KR102472483B1 (en) | Cosmetic composition having exfoliating effect and moisturizing effect | |
| CN107468610A (en) | A kind of extraction product of rice bran shell and its application in facial-care | |
| CA2365660A1 (en) | Treatment for skin | |
| KR102269198B1 (en) | Vanishing cream cosmetic composition for exfoliation of skin and preparation method thereof | |
| KR101956155B1 (en) | Skin external composition comprising theanine derivative | |
| JP2011006372A (en) | Beauty treatment | |
| KR100840988B1 (en) | Formulation containing alginate for skin moisturizing and soothing effect | |
| JP2021531286A (en) | Cosmetic composition for exfoliating keratin | |
| KR101120660B1 (en) | COSMETIC COMPOSITION COMPRISING a-HYDROXY ACID AND ETHER SURFACTANT | |
| KR20200065273A (en) | Liquid cosmetic composition | |
| KR0172664B1 (en) | Cosmetic compostions for face washing | |
| KR100521787B1 (en) | Composition for enhancing skin or hair | |
| KR100890712B1 (en) | Pore-minimizing cosmetic composition containing kaolin | |
| KR101557422B1 (en) | Cleansing composition and cosmetic composition with the extract of Styrax japonica | |
| US20240130950A1 (en) | Liquid crystal composition including ceramide and method of preparing the same | |
| US20240225987A9 (en) | Liquid crystal composition including ceramide and method of preparing the same | |
| KR20050095011A (en) | Washable cleansing cosmetic composition | |
| KR20090099193A (en) | Anti-wrinkle cosmetic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |